James F. Oliviero III Sells 15,090 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 15,090 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total value of $60,963.60. Following the completion of the transaction, the chief executive officer now owns 3,759,929 shares in the company, valued at approximately $15,190,113.16. This trade represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Checkpoint Therapeutics Stock Down 0.7 %

NASDAQ CKPT opened at $4.01 on Friday. Checkpoint Therapeutics, Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The business has a 50 day moving average price of $3.42 and a two-hundred day moving average price of $3.31. The stock has a market cap of $195.82 million, a PE ratio of -2.18 and a beta of 1.21.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. Sell-side analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Trading of Checkpoint Therapeutics

Several large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics in the third quarter valued at about $30,000. SBI Securities Co. Ltd. purchased a new position in shares of Checkpoint Therapeutics during the 4th quarter valued at approximately $32,000. PUREfi Wealth LLC acquired a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth approximately $32,000. Stifel Financial Corp bought a new stake in shares of Checkpoint Therapeutics in the fourth quarter worth $32,000. Finally, Ameriflex Group Inc. acquired a new stake in Checkpoint Therapeutics in the fourth quarter valued at $32,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on CKPT. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 price target (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. HC Wainwright restated a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday, March 31st.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.